309 related articles for article (PubMed ID: 11068290)
21. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma.
Raman JD; Sosa RE; Vaughan ED; Scherr DS
Urology; 2007 Feb; 69(2):251-4. PubMed ID: 17320658
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of angiogenesis in superficial bladder cancer.
Stavropoulos NE; Bouropoulos C; Ioachim IE; Michael M; Hastazeris K; Tsimaris I; Kalogeras D; Liamis Z; Stefanaki S; Agnantis NI
Int Urol Nephrol; 2004; 36(2):163-7. PubMed ID: 15368686
[TBL] [Abstract][Full Text] [Related]
23. Accumulation of nuclear p53 and tumor progression in bladder cancer.
Esrig D; Elmajian D; Groshen S; Freeman JA; Stein JP; Chen SC; Nichols PW; Skinner DG; Jones PA; Cote RJ
N Engl J Med; 1994 Nov; 331(19):1259-64. PubMed ID: 7935683
[TBL] [Abstract][Full Text] [Related]
24. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67.
Tut VM; Braithwaite KL; Angus B; Neal DE; Lunec J; Mellon JK
Br J Cancer; 2001 Jan; 84(2):270-5. PubMed ID: 11161387
[TBL] [Abstract][Full Text] [Related]
25. Prognostic interest in discriminating muscularis mucosa invasion (T1a vs T1b) in nonmuscle invasive bladder carcinoma: French national multicenter study with central pathology review.
Rouprêt M; Seisen T; Compérat E; Larré S; Mazerolles C; Gobet F; Fetissof F; Fromont G; Safsaf A; d'Arcier BF; Celhay O; Validire P; Rozet F; Irani J; Soulié M; Pfister C;
J Urol; 2013 Jun; 189(6):2069-76. PubMed ID: 23201497
[TBL] [Abstract][Full Text] [Related]
26. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of p53 nuclear overexpression in patients of muscle invasive urinary bladder carcinoma treated with cystectomy.
Hemal AK; Khaitan A; Dinda AK; Gupta NP; Seth A; Dogra PN; Nabi G
Urol Int; 2003; 70(1):42-6. PubMed ID: 12566814
[TBL] [Abstract][Full Text] [Related]
28. p53 nuclear accumulation is not associated with decreased disease-free survival in patients with node positive transitional cell carcinoma of the bladder.
Fleshner N; Kapusta L; Ezer D; Herschorn S; Klotz L
J Urol; 2000 Oct; 164(4):1177-82. PubMed ID: 10992361
[TBL] [Abstract][Full Text] [Related]
29. Clinical panurothelial disease in patients with superficial bladder tumors: therapeutic implications.
Solsona E; Iborra I; Ricos JV; Monros JL; Rubio J; Almenar S
J Urol; 2002 May; 167(5):2007-11. PubMed ID: 11956428
[TBL] [Abstract][Full Text] [Related]
30. Flow cytometric DNA and p53 analysis in superficially infiltrating bladder carcinoma.
Vatne V; Maartmann-Moe H; Hoestmark J
Anticancer Res; 1994; 14(6B):2735-8. PubMed ID: 7872710
[TBL] [Abstract][Full Text] [Related]
31. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder.
Dekairelle AF; Tombal B; Cosyns JP; Gala JL
Clin Cancer Res; 2005 Jul; 11(13):4724-32. PubMed ID: 16000567
[TBL] [Abstract][Full Text] [Related]
32. P53 expression, ploidy and progression in pT1 transitional cell carcinoma of the bladder.
Thomas DJ; Robinson MC; Charlton R; Wilkinson S; Shenton BK; Neal DE
Br J Urol; 1994 May; 73(5):533-7. PubMed ID: 8012776
[TBL] [Abstract][Full Text] [Related]
33. Prognostic role of the tumor-associated tissue inflammatory reaction in transitional bladder cell carcinoma.
Cai T; Nesi G; Boddi V; Mazzoli S; Dal Canto M; Bartoletti R
Oncol Rep; 2006 Aug; 16(2):329-34. PubMed ID: 16820911
[TBL] [Abstract][Full Text] [Related]
34. [Value of the proliferation status (PCNA) and p53 immunohistochemistry as a prognostic factor for the clinical course of superficial cancer of the urinary bladder].
Kuczyk MA; Serth J; Bokemeyer C; Hervatin C; Oelke M; Oelert F; Höfner K; Jonas U
Urologe A; 1995 Mar; 34(2):146-52. PubMed ID: 7754587
[TBL] [Abstract][Full Text] [Related]
35. p53 expression predicts progression and poor survival in T1 bladder tumours.
Llopis J; Alcaraz A; Ribal MJ; Solé M; Ventura PJ; Barranco MA; Rodriguez A; Corral JM; Carretero P
Eur Urol; 2000 Jun; 37(6):644-53. PubMed ID: 10828662
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of mucosal aneuploidy in stage Ta/T1 grade 3 carcinoma of the bladder.
Norming U; Tribukait B; Nyman CR; Nilsson B; Wang N
J Urol; 1992 Nov; 148(5):1420-6; discussion 1426-7. PubMed ID: 1433541
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of static cytometry in transitional cell carcinoma of the bladder: recurrence rate and survival in a group of patients at 10 years follow-up.
Cai T; Margallo E; Nesi G; Giubilei G; Rizzo M; Bartoletti R
Oncol Rep; 2006 Jan; 15(1):213-9. PubMed ID: 16328058
[TBL] [Abstract][Full Text] [Related]
38. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical detection of p53 protein in transitional cell carcinoma of the bladder in correlation to DNA ploidy and pathohistological stage and grade.
al-Abadi H; Nagel R; Neuhaus P
Cancer Detect Prev; 1998; 22(1):43-50. PubMed ID: 9466048
[TBL] [Abstract][Full Text] [Related]
40. S-phase fraction in superficial urothelial carcinoma of the bladder--a prospective, long-term, follow-up study.
Falkman K; Tribukait B; Nyman CR; Larsson P; Norming U
Scand J Urol Nephrol; 2004; 38(4):278-84. PubMed ID: 15669586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
